Influence of @entity5962 expression on the mammographic appearance of XXXX detected at screening.

@entity5 @entity1 @entity5962 @entity0
PURPOSE: To determine whether @entity5962 loss causes @entity5 ( @entity5 ) detected at mammographic screening to have different mammographic appearances than do @entity5 with normal @entity5962 expression. MATERIALS AND METHODS: This study design had hospital ethics committee approval; informed consent was waived. Membranous expression of @entity5962 was assessed immunohistochemically in @entity1 younger than 70 years from a consecutive series of 1944 operable invasive @entity0 . Of those, 276 NLC cases (age range, 45-70 years) were common to a prospectively collected database of @entity0 detected at screening. The mammographic features of 131 @entity5 with reduced @entity5962 expression were compared with those of 145 @entity5 with normal @entity5962 expression. RESULTS: @entity5 with @entity5962 loss were more likely to manifest as an ill-defined mass and less likely to manifest noncomedo microcalcifications at mammography than were @entity5 with normal @entity5962 expression (47 [35.9%] of 131 vs 35 [24.1%] of 145, P = .03; and one [0.8%] of 131 versus 13 [9%] of 145, P = .001; respectively). @entity5 with @entity5962 loss were significantly larger (>or=15 mm) than @entity5 with normal @entity5962 expression (71 [54.2%] of 131 @entity5 vs 57 [39.3%] of 145; P = .01). Both groups had a similar distribution of grade, @entity5 type, nodal metastases, and vascular invasion. CONCLUSION: Invasive @entity5 with reduced @entity5962 expression detected at screening are more likely to appear as ill-defined masses and less likely to manifest noncomedo microcalcifications than are @entity5 with normal @entity5962 expression. @entity5 with reduced @entity5962 expression appear to have mammographic features that make them difficult to detect at small sizes.
